UroGen Pharma (NASDAQ:URGN) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings
UroGen Pharma beat estimated earnings by 6.02%, reporting an EPS of $-1.25 versus an estimate of $-1.33.
Revenue was up $6.08 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.1 which was followed by a 2.0% drop in the share price the next day.
Here's a look at UroGen Pharma's past performance:
| Quarter | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|
| EPS Estimate | -1.17 | -1.29 | -1.27 | -1.29 |
| EPS Actual | -1.27 | -1.35 | -1.17 | -1.17 |
| Revenue Estimate | 16.49M | 15.42M | 10.21M | 9.05M |
| Revenue Actual | 16.17M | 11.35M | 13.03M | 7.49M |
To track all earnings releases for UroGen Pharma visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
